Vistagen Inc. (NASDAQ: VTGN) had itself a Wednesday. The penny stock surged after the company dropped preliminary findings from the open-label extension portion of its PALISADE-4 Phase 3 trial, which is testing intranasal fasedienol for acute social anxiety disorder.

Here's the thing about that trial, though. The main event, the primary endpoint in the overall study population, was a miss. PALISADE-4 did not hit its primary endpoint. That's the headline you'd normally lead with. But data released in June identified a statistically significant benefit in a post-hoc analysis of patients with very severe social anxiety, and that's the thread Vistagen has been pulling on ever since.

What the Extension Data Actually Shows

The extension trial involved 322 adult participants. Analysis through a July 24, 2026 data cut-off revealed no new drug-related safety findings or serious adverse events linked to fasedienol over 12 months of exposure.

Overall discontinuation due to adverse events reached 1.6%, with zero participant withdrawals attributed to the drug itself. More than 95% of adverse events were mild or moderate in severity. For a drug that's sprayed up your nose, that's the kind of safety profile you want to see.

The Efficacy Numbers

On the clinician-administered Liebowitz Social Anxiety Scale, subjects entered with a very severe mean baseline score of 99.3. Mean improvements reached 20.2 points at month one, 24.6 points at month two, 29.1 points at month three, and 31.4 points by month four.

At month four, 65% of subjects experienced a 20-point or greater improvement. Mean score changes at month two reflected a clinically meaningful reduction of two severity categories across fear, anxiety, and avoidance subscales.

Patient-reported assessments on the Social Phobia Inventory backed this up. Starting from a severe baseline mean score of 48.5, participants showed a 10.5-point mean improvement at month one and a 14.9-point improvement at month four.

The Analyst Says Not So Fast

Vistagen is preparing to meet with the FDA during the current quarter to discuss a proposed new registrational Phase 3 clinical trial. That meeting matters a lot, because the path forward is not entirely clear.

William Blair noted that the PALISADE-4 OLE data add incremental evidence to fasedienol's clinical data package supportive of a treatment benefit, though the firm cautioned against overinterpretation of the open-label data.

Analyst Myles Minter wrote that it is hard to gain conviction around open-label fasedienol data currently given a lack of placebo control, and Phase 3 studies have shown mixed data.

Minter further notes that it is unclear whether a single additional registrational study using LSAS as the primary endpoint would be sufficient to support filing, or whether the agency could require two additional pivotal studies given the proposed shift away from the historical PALISADE study design. PALISADE-2, for what it's worth, was a positive study.

William Blair maintains the Market Perform rating.

VTGN Price Action: Vistagen Therapeutics shares were up 58.55% to $0.39 during premarket trading on Wednesday, according to market data.